|Bid||0.8507 x 1000|
|Ask||1.2000 x 800|
|Day's Range||0.8300 - 0.9399|
|52 Week Range||0.5500 - 2.0100|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.00|
NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced the funding of a study for KPC34, for pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA). PDA is considered the deadliest of major cancers and patients are in desperate need of improved therapies. PDA is caused by chronic inflammatory stress associated with the increasingly common afflictions of obesity, type 2 diabetes, and pancreatitis, exacerbated by smoking and drinking. KPC34 is a candidate therapeutic because it is activated preferentially inside tumor cells to release an inhibitor of DNA replication and a separate tumor promotion inhibitor. Annually, more than 350,000 new cases of pancreatic cancer are diagnosed across the world. According to the American Society of Clinical Oncology, a six-month course of gemcitabine, the chemotherapy drug typically used to treat advanced pancreatic cancer, costs about $23,500.
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Twilio shares were on the rise on an “outperform” rating reiterated from an Oppenheimer analyst last week while Spherix Incorporated shares popped on news ...
From renting out an unused road bike, to running a fleet of hundreds of electric scooters, Mellow provides a flexible entry for anyone interested in the growing shared vehicles space. Additional information about the investment will be available in the Form 8-K, filed by Spherix with the Securities and Exchange Commission.
NEW YORK, Oct. 29, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has added Dr. Rana Quraishi to the Company's Advisory Board to assist the Company in evaluating potential opportunities in the biopharmaceutical area. Dr. Rana Quraishi is the Director of New Ventures, at UM Ventures University of Maryland, Baltimore. UM Ventures is a joint initiative bringing the University of Maryland, Baltimore and University of Maryland, College Park together to commercialize discoveries and create economic impact by engaging partners in industry and social ventures. Dr. Quraishi has a Ph.D. in Molecular Biology and Biochemistry from Columbia University where she was also an undergraduate and an M.S. from Harvard University.
Las Vegas, Nevada--(Newsfile Corp. - October 25, 2018) - Early stage biotechnology and pharmaceutical companies often present a quandary for investors. The technology is generally difficult to understand and investors just can't fully picture the potential.Except when that picture is an absolutely stunning, must-see video from Wake Forest University of a mouse paralyzed by Acute Lymphoblastic Leukemia restored to mobility in two days by a drug now headed to the patent portfolio of ...
Anthony Hayes, CEO of Spherix, stated, "This remarkable video demonstrates the tremendous potential for this drug to treat ALL. The video was part of a written submission on KPC34 to PLOS OneTM a peer reviewed medical journal.
NEW YORK, Oct. 11, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that it has entered into a merger agreement with CBM BioPharma, Inc. ("CBM") that will transform Spherix into an innovative pharmaceutical company with pioneering drugs and treatments focused on the multibillion dollar oncology therapeutics market. CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin. CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
NEW YORK, Aug. 15, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) a technology development company committed to the fostering of innovation and monetization of intellectual property, today announced it has terminated its merger agreement with DatChat. After strategic meetings with DatChat, both organziations believe there is a more effective strategy that will have the best opportunity for long-term growth. The Spherix Board of Directors determined that a strategic equity investment in DatChat will provide a better strategy for shareholders and allow Spherix to benefit from DatChat's platform and projected growth.
Stock Research Monitor: ONE, SPEX, and TISI LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on MCO sign up now at www.wallstequities.com/registration . WallStEquities.com has ...
For Spherix Incorporated’s (NASDAQ:SPEX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. SPEX is exposed toRead More...
In this article, I’m going to take a look at Spherix Incorporated’s (NASDAQ:SPEX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
Spherix and DatChat have been working together to enhance the user experience. The result is Advanced Screenshot Protection that prevents the recipients of your messages and images from being able to take screenshots. If a recipient tries to take a screenshot of a message or image sent from a DatChat user, the recipient will now only capture a blank screen and the sender will be notified that a screenshot was attempted. Additionally, the advanced screenshot prevention protects against other forms of screen capture, including iOS screen recording, AirPlay screen mirroring and QuickTime screen recording.
While small-cap stocks, such as Spherix Incorporated (NASDAQ:SPEX) with its market cap of US$9.13M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...
Hayes to Discuss the Company's Recent Transformational Acquisition of DatChat NEW YORK , May 8, 2018 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX), a technology company committed to advancing innovation ...
- Company to issue 11.5m fewer shares than initially contemplated - Effective Purchase Price Reduction of $15m - Renowned Cyber-Security Veteran Gregg Blattner to join the Board of Directors NEW YORK , ...
Company Details New Opportunities Following DatChat Acquisition NEW YORK , April 11, 2018 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) a technology company committed to advancing innovation by participation ...
One of the driving forces of our Company is our pursuit of business strategies and investments that stand to benefit from both the rapid pace of technological change and ever changing complexities of consumer behavior. Spherix's proposed merger with DatChat provides a working solution to the growing privacy problem.
NEW YORK, March 27, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) announced today that the Company has closed an investment in TheBit Daily LLC ("TheBit"), a development stage media and education platform focused on the blockchain and cryptocurrency space. The site provides strategic and intelligently condensed insight to this exciting technology. For more information, please visit: www.thebitdaily.com. TheBit Daily aims to lower the barrier of entry into the blockchain and cryptocurrency technology fields. TheBit informs readers, who range from beginners to experts, through its easy to understand "Guides" on the main concepts behind blockchain and cryptocurrencies. TheBit offers a free custom-curated newsletter that apprises users on the latest updates and events impacting the blockchain and cryptocurrencies sectors.
Improvement in profitability and outperformance against the industry can be important characteristics in a stock for some investors. Below, I will assess Spherix Incorporated’s (NASDAQ:SPEX) track record on a highRead More...
NEW BRUNSWICK, N.J., March 19, 2018 /PRNewswire/ -- DatChat Incorporated ("DatChat"), an encrypted personal privacy platform, focused on encrypted communication, internet privacy and digital rights management, today updated shareholders on its merger agreement with Spherix Incorporated (SPEX), its continued blockchain development and mining efforts. This technology is in the development stage.
NEW YORK, March 15, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX), a technology development company committed to the fostering of innovation and monetization of intellectual property, today announced that it has priced a registered public offering on a "best efforts" basis of an aggregate of 2,222,222 shares of common stock at a price to the public of $1.35 per share. The offering is expected to close on or about March 19, 2018, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds of the offering are anticipated to be approximately $3 million. After deducting the placement agent's commission and other estimated offering expenses payable by Spherix, the net proceeds to Spherix are anticipated to be approximately $2.7 million. Spherix intends to use the net proceeds from the offering for working capital and general corporate purposes.
Stock Monitor: Performant Financial Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on Spherix Inc. (NASDAQ: SPEX ). If ...
NEW YORK, March 14, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX), a technology development company committed to the fostering of innovation and monetization of intellectual property, today announced a proposed registered public offering of its common stock. The offering is being made on a "best efforts" basis and subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Laidlaw & Company (UK) Ltd. is acting as exclusive placement agent for the offering.
NEW YORK, March 13, 2018 /PRNewswire/ -- Spherix Incorporated (SPEX) a technology development company committed to the fostering of innovation and monetization of intellectual property, today announced that it has entered into a definitive purchase agreement to acquire 100% ownership of DatChat Inc. DatChat is a privately held personal privacy platform, focused on Encrypted Communication, Internet Security and Digital Rights Management. Additionally, the Company is expanding its platform to include a peer-to-peer secure email system that will be built on Ethereum blockchain technology.
NEW YORK, Feb. 22, 2018 /PRNewswire/ -- Hoth Therapeutics Inc. ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today that it has completed its Series A financing totaling $3 million, before expenses, to fund operations and advance Hoth's BioLexa Platform. Laidlaw & Co (UK) Ltd. ("Laidlaw") in New York served as the sole placement agent.